CRNX — Crinetics Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.03bn
- $1.68bn
- $1.04m
- 48
- 11
- 45
- 27
Annual cashflow statement for Crinetics Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -73.8 | -108 | -164 | -215 | -298 |
| Depreciation | |||||
| Non-Cash Items | 10.5 | 17 | 29.1 | 39.1 | 58 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.376 | 1.1 | 18.6 | 8.04 | 11.6 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -62 | -88.6 | -115 | -166 | -226 |
| Capital Expenditures | -0.186 | -0.436 | -1.66 | -4.69 | -3.84 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.403 | -56 | -172 | -196 | -571 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.217 | -56.5 | -174 | -200 | -575 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 115 | 253 | 122 | 389 | 1,010 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 52.8 | 108 | -167 | 22.2 | 210 |